To investigate whether CSF1R is of relevance for AML, we utilized an investigational tyrosine kinase inhibitor (TKi) in clinic trials, narazaciclib (HX301 or ON123300), which possesses strong inhibitory potency against CSF1R. This evidence concerns the gene CSF1R and acute myeloid leukemia.